Important Note: The information provided on any Fast Facts document is intended for use as a general eligibility checklist only. FAST FACTS ARE NOT TO BE USED AS TREATMENT SCHEMA. Contact GRCOP at (616) 391-1230 for specific patient eligibility requirements and the formal treatment plan.

Recently Activated Protocols

Brain/CNS

Cancer Type:	Anaplastic Glioma
Research Base:	NCCTG
Protocol:	N0577
	Fast Facts

N0577: Phase III Intergroup Study of Radiotherapy versus Temozolomide alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma

Physician Summary: > Age 18; Staging: Co-deleted 1p/19q Anaplastic Glioma; Treatment: RT vs Temozolomide alone vs RT with concomitant & Adjuvant Temozolomide.

Cancer Type:	Glioblastoma
Research Base:	NCCTG
Protocol:	N057K
	Fast Facts

NCCTG N057K: Phase I/II Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ) Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed Glioblastoma

Physician Summary: > Age 18; Grade IV Astrocytoma (GBM); Treatment: Everolimus + RT + Temozolomide f/b Everolimus + Temozolomide f/b Everolimus

Cancer Control

Cancer Type:	Ovarian,Peritoneal of Fallopian Tube
Research Base:	GOG
Protocol:	0256
	Fast Facts

GOG 0256: A PROSPECTIVE STUDY OF COGNITIVE FUNCTION DURING CHEMOTHERAPY FOR FRONT-LINE TREATMENT IN OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE CANCER

Physician Summary:

Cancer Type:	Esophageal
Research Base:	RTOG
Protocol:	0436
	Fast Facts

RTOG 0436: A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without Surgery

Physician Summary: > Age 18; T1N1M0; T2-4, Any N, M0; Any T, and N, M1a. Treatment: Concurrent Radiation with Paclitaxel and Cisplatin, w/ or w/o Cetuximab

GYN

Cancer Type:	Ovarian,Peritoneal of Fallopian Tube
Research Base:	GOG
Protocol:	0256
	Fast Facts

GOG 0256: A PROSPECTIVE STUDY OF COGNITIVE FUNCTION DURING CHEMOTHERAPY FOR FRONT-LINE TREATMENT IN OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE CANCER

Physician Summary:

Leukemia

Cancer Type:	ALL
Research Base:	SWOG
Protocol:	S0805
	Fast Facts

SWOG S0805: Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) with or without Allogeneic Stem Cell Transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (a BMT Study)

Physician Summary: > Age 18 and < Age 50; Philadelphia or Oncogene Bcr-Abl Positive. Treatment: Hyper-CVAD/Dasatinib w/ High Dose MTX and Cytarabine/Dasatinib f/b Maintenence Vincristine/Pred/Dasatinib

Melanoma

Cancer Type:	Melanoma Mets
Research Base:	Sarah Cannon
Protocol:	MEL 19
	Fast Facts

MEL 19: A Phase II Study of Everolimus in Combination with Paclitaxel and Carboplatin in Patients with Metastatic Melanoma

Physician Summary:

> Age 18; Stage III or IV; No prior Cytotoxic or Biologic TX; Prior Immunotherapy allowed. Treatment: Paclitaxel and Carboplatin w/ Oral Everolimus